

Trial	Drug (if applicable)	Patent No.	Filed Date	Petitioner(s)	Patent Owner(s)	Inst. Dec.	Outcome	Details of FWD
<Information obtained primarily from Lex Machina™ and public sources on the Internet. If any errors are identified, please contact Lisa Mandrusiak at Oblon.>								
IPR2017-00011	Adderall XR®; Mydayis®	RE41148	4-Oct-16	Mylan N.V.; Mylan, Inc.; Mylan Pharmaceuticals, Inc.	Shire LLC	Denied	N/A	N/A
IPR2017-00013		7,563,584	4-Oct-16	Fluidigm Corp.	The Board of Trustees of the Leland Stanford Junior University	Instituted	Settled post-institution	N/A
IPR2017-00014		7,695,926	4-Oct-16	Fluidigm Corp.	The Board of Trustees of the Leland Stanford Junior University	Instituted	Settled post-institution	N/A
IPR2017-00026		7,109,035	5-Oct-16	Spectrum Laboratories, LLC	Woodstock Enterprises, Inc.	Denied	N/A	N/A
IPR2017-00028		9,102,762	7-Oct-16	LFB Biopharmaceuticals Ltd.; rEVO Biologics, Inc.; LFB Hemoderivados E Biotechnologia LTDA; et al.	Novo Nordisk Health Care AG	Instituted	Final written decision	All inst. claims upheld
IPR2017-00041	Xarelto®	7,157,456	7-Oct-16	Mylan Pharmaceuticals, Inc.	Bayer Intellectual Property GmbG	N/A	Settled pre-institution	N/A
IPR2017-00042	Xarelto®	7,585,860	7-Oct-16	Mylan Pharmaceuticals, Inc.	Bayer Intellectual Property GmbG	N/A	Settled pre-institution	N/A
IPR2017-00043	Xarelto®	7,592,339	7-Oct-16	Mylan Pharmaceuticals, Inc.	Bayer Intellectual Property GmbG	N/A	Settled pre-institution	N/A
IPR2017-00047		6,331,415	11-Oct-16	Merck Sharp & Dohme Corp.	City of Hope; Genentech, Inc.	Instituted	Settled post-institution	N/A
IPR2017-00054		8,236,504	14-Oct-16	Thermo Fisher Scientific, Inc.	Bio-Rad Laboratories, Inc.	Instituted	Settled post-institution	N/A
IPR2017-00055		8,236,504	14-Oct-16	Thermo Fisher Scientific, Inc.	Bio-Rad Laboratories, Inc.	Instituted	Settled post-institution	N/A
IPR2017-00162		9,115,071	31-Oct-16	Celanese International Corporation	Daicel Corporation	Instituted	Claims disclaimed	N/A
IPR2017-00163		8,940,932	31-Oct-16	Celanese International Corporation	Daicel Corporation	Instituted	Final written decision	Some claims upheld
IPR2017-00164		9,162,958	31-Oct-16	Celanese International Corporation	Daicel Corporation	Instituted	Claims disclaimed	N/A
IPR2017-00165		9,073,843	31-Oct-16	Celanese International Corporation	Daicel Corporation	Instituted	Final written decision	All inst. claims unpatentable
IPR2017-00166		9,006,483	31-Oct-16	Celanese International Corporation	Daicel Corporation	Instituted	Final written decision	All inst. claims unpatentable
IPR2017-00172		7,064,197	3-Nov-16	Becton, Dickinson, and Co.	Enzo Life Sciences, Inc.	Denied	Final written decision	All inst. claims unpatentable
IPR2017-00181		7,064,197	3-Nov-16	Becton, Dickinson, and Co.	Enzo Life Sciences, Inc.	Denied	Final written decision	All inst. claims unpatentable
IPR2017-00190	Jublia®	7,214,506	2-Nov-16	Acrux Ltd; Acrux DDS PTY Ltd.	Kaken Pharmaceutical Co., Ltd; Valeant Pharmaceuticals Int'l	Instituted	Final written decision	All inst. claims unpatentable

IPR2017-00195	Copaxone®	9,155,776	2-Nov-16	Mylan N.V.; Mylan, Inc.; Mylan Pharmaceuticals, Inc.; Mylan Teoranta	Yeda Research and Development Co. Ltd.	N/A	Procedurally dismissed	N/A
IPR2017-00200	Suboxone®	8,603,514	4-Nov-16	Mylan, Inc.; Mylan Technologies, Inc; Mylan N.V.; et al.	MonoSol Rx LLC	Instituted	Settled post-institution	N/A
IPR2017-00287	Abilify®	9,125,939	17-Nov-16	Alkermes, Inc.; Alkermes plc; Alkermes Pharma Ireland Limited	Otsuka Pharmaceutical Co., Ltd.	Denied	N/A	N/A
IPR2017-00305		8,815,955	21-Nov-16	Omniactive Health Technolgies, Inc.; OmniActive Health Technologies Ltd.	Kemin Industries, Inc.	N/A	Settled pre-institution	N/A
IPR2017-00306		9,226,940	21-Nov-16	Omniactive Health Technolgies, Inc.; OmniActive Health Technologies Ltd.	Kemin Industries, Inc.	N/A	Settled pre-institution	N/A
IPR2017-00323	Cialis®	6,943,166	22-Nov-16	Mylan N.V.; Mylan, Inc.; Mylan Pharmaceuticals, Inc.	ICOS Corporation	Instituted	Settled post-institution	N/A
IPR2017-00378		8,562,999	1-Dec-16	Merck Sharp & Dohme Corp.; Merck & Co Inc.	Wyeth LLC	Instituted	Final written decision	Some claims upheld
IPR2017-00380		8,562,999	1-Dec-16	Merck Sharp & Dohme Corp.; Merck & Co Inc.	Wyeth LLC	Instituted	Final written decision	Some claims upheld
IPR2017-00390		8,562,999	2-Dec-16	Merck Sharp & Dohme Corp.	Wyeth LLC	Instituted	Final written decision	All inst. claims unpatentable
IPR2017-00391		6,017,221	2-Dec-16	Samsung Electronics Co., Ltd; Micron Technology, Inc.; GLOBALFOUNDRIES U.S., Inc.; Intel Corporation	Daniel L. Flamm	Instituted	Final written decision	All inst. claims unpatentable
IPR2017-00412	Cialis®	6,943,166	6-Dec-16	MonoSol Rx LLC	ICOS Corporation	Denied	N/A	N/A
IPR2017-00503		9,066,920	16-Dec-16	Insys Development Company, Inc.	GW Pharma Ltd.	Instituted	Final written decision	Some claims upheld
IPR2017-00547		9,327,025	28-Dec-16	VDF FutureCeuticals, Inc.	Hanif Kazerooni; Bahram Nasernejad; Akbar Zare; Abbas Abdolmalaki	Instituted	Final written decision	All inst. claims unpatentable
IPR2017-00566	Restasis®	8,648,048	6-Jan-17	Lupin Ltd.; Lupin Inc.; Lupin Pharmaceuticals, Inc.; Lupin Atlantis Holdings S.A.; et al.	Allergan, Inc.	Instituted	Settled post-institution	N/A
IPR2017-00567	Restasis®	8,629,111	6-Jan-17	Lupin Ltd.; Lupin Inc.; Lupin Pharmaceuticals, Inc.; Lupin Atlantis Holdings S.A.; et al.	Allergan, Inc.	Instituted	Settled post-institution	N/A

IPR2017-00568	Restasis®	8,633,162	6-Jan-17	Lupin Ltd.; Lupin Inc.; Lupin Pharmaceuticals, Inc.; Lupin Atlantis Holdings S.A.; et al.	Allergan, Inc.	Instituted	Settled post-institution	N/A
IPR2017-00569	Restasis®	9,248,191	6-Jan-17	Lupin Ltd.; Lupin Inc.; Lupin Pharmaceuticals, Inc.; Lupin Atlantis Holdings S.A.; et al.	Allergan, Inc.	Instituted	Settled post-institution	N/A
IPR2017-00570	Restasis®	8,642,556	6-Jan-17	Lupin Ltd.; Lupin Inc.; Lupin Pharmaceuticals, Inc.; Lupin Atlantis Holdings S.A.; et al.	Allergan, Inc.	Instituted	Settled post-institution	N/A
IPR2017-00571	Restasis®	8,685,930	6-Jan-17	Lupin Ltd.; Lupin Inc.; Lupin Pharmaceuticals, Inc.; Lupin Atlantis Holdings S.A.; et al.	Allergan, Inc.	Instituted	Settled post-institution	N/A
IPR2017-00572		8,252,571	4-Jan-17	Reactive Surfaces Ltd., LLP	Regents of the University of Minnesota; Toyota Motor Corporation.	Instituted	Claims disclaimed	N/A
IPR2017-00576	Restasis®	8,685,930	6-Jan-17	Teva Pharmaceuticals Industries, Inc.; Teva Pharmaceuticals USA, Inc.	Allergan, Inc.	Instituted	Procedurally dismissed	N/A
IPR2017-00578	Restasis®	8,629,111	6-Jan-17	Teva Pharmaceuticals Industries, Inc.; Teva Pharmaceuticals USA, Inc.	Allergan, Inc.	Instituted	Procedurally dismissed	N/A
IPR2017-00579	Restasis®	9,642,556	6-Jan-17	Teva Pharmaceuticals Industries, Inc.; Teva Pharmaceuticals USA, Inc.	Allergan, Inc.	Instituted	Procedurally dismissed	N/A
IPR2017-00583	Restasis®	8,633,162	6-Jan-17	Teva Pharmaceuticals Industries, Inc.; Teva Pharmaceuticals USA, Inc.	Allergan, Inc.	Instituted	Procedurally dismissed	N/A
IPR2017-00585	Restasis®	8,648,048	6-Jan-17	Teva Pharmaceuticals Industries, Inc.; Teva Pharmaceuticals USA, Inc.	Allergan, Inc.	Instituted	Procedurally dismissed	N/A
IPR2017-00586	Restasis®	9,248,191	6-Jan-17	Teva Pharmaceuticals Industries, Inc.; Mylan Pharmaceuticals, Inc.; Teva Pharmaceuticals USA, Inc.; et al.	Allergan, Inc.	Instituted	Procedurally dismissed	N/A
IPR2017-00594	Restasis®	8,685,930	6-Jan-17	Akorn, Inc.	Allergan, Inc.	Instituted	Procedurally dismissed	N/A
IPR2017-00596	Restasis®	8,629,111	6-Jan-17	Akorn, Inc.	Allergan, Inc.	Instituted	Procedurally dismissed	N/A
IPR2017-00598	Restasis®	8,642,556	6-Jan-17	Akorn, Inc.	Allergan, Inc.	Instituted	Procedurally dismissed	N/A
IPR2017-00599	Restasis®	8,633,162	6-Jan-17	Akorn, Inc.	Allergan, Inc.	Instituted	Procedurally dismissed	N/A
IPR2017-00600	Restasis®	8,648,048	6-Jan-17	Akorn, Inc.	Allergan, Inc.	Instituted	Procedurally dismissed	N/A
IPR2017-00601	Restasis®	9,248,191	6-Jan-17	Akorn, Inc.	Allergan, Inc.	Instituted	Procedurally dismissed	N/A
IPR2017-00631	Symbicort®	7,759,328	9-Jan-17	Complex Innovations, LLC	Astrazeneca AB	Denied	N/A	N/A

IPR2017-00643	Levothyroxine sodium	9,168,238	19-Jan-17	Mylan, Inc.; Mylan Institutional Inc.; Mylan N.V.	Fresenius Kabi USA, LLC	N/A	Settled pre-institution	N/A
IPR2017-00644	Levothyroxine sodium	9,168,239	19-Jan-17	Mylan, Inc.; Mylan Institutional Inc.; Mylan N.V.	Fresenius Kabi USA, LLC	N/A	Settled pre-institution	N/A
IPR2017-00645	Levothyroxine sodium	9,006,289	19-Jan-17	Mylan, Inc.; Mylan Institutional Inc.; Mylan N.V.	Fresenius Kabi USA, LLC	N/A	Settled pre-institution	N/A
IPR2017-00665	Mydayis®	8,846,100	13-Jan-17	Amerigen Pharmaceuticals Ltd.	Shire LLC	N/A	Settled pre-institution	N/A
IPR2017-00731	Herceptin®	7,846,441	20-Jan-17	Pfizer, Inc.; Hospira, Inc.	Genentech, Inc.	Denied	N/A	N/A
IPR2017-00737	Herceptin®	7,892,549	20-Jan-17	Pfizer, Inc.; Hospira, Inc.	Genentech, Inc.	Instituted	Final written decision	All inst. claims unpatentable
IPR2017-00739	Herceptin®	7,892,549	20-Jan-17	Pfizer, Inc.; Hospira, Inc.	Genentech, Inc.	Denied	N/A	N/A
IPR2017-00745		9,078,905	27-Jan-17	Bioriginal Food & Science Corp.; Pharmachem Laboratories, Inc.; Avoca Inc.; SRR Invest AS; et al.	Aker BioMarine Antarctic AS	Instituted	Final written decision	All inst. claims unpatentable
IPR2017-00746		9,028,877	3-Feb-17	Avoca Inc.; Pharmacehm Laboratories, Inc.; SRR Invest AS; Rimfrost Holding AS; et al.	Aker BioMarine Antarctic AS	Instituted	Final written decision	All inst. claims unpatentable
IPR2017-00747		9,078,905	27-Jan-17	Bioriginal Food & Science Corp.; Pharmachem Laboratories, Inc.; Avoca Inc.; SRR Invest AS; et al.	Aker BioMarine Antarctic AS	Instituted	Final written decision	All inst. claims upheld
IPR2017-00748		9,028,877	3-Feb-17	Avoca Inc.; Pharmacehm Laboratories, Inc.; SRR Invest AS; Rimfrost Holding AS; et al.	Aker BioMarine Antarctic AS	Instituted	Final written decision	All inst. claims upheld
IPR2017-00762		9,353,050	24-Jan-17	Aurobindo Pharma Ltd.; AuroMedics Pharma LLC	Apicore US LLC	N/A	Settled pre-institution	N/A
IPR2017-00804	Herceptin®	6,627,196	30-Jan-17	Samsung Bioepis Co., Ltd.; Pfizer, Inc.; Hospira, Inc.	Genentech, Inc.	Instituted	Final written decision	All inst. claims upheld
IPR2017-00805	Herceptin®	7,371,379	30-Jan-17	Samsung Bioepis Co., Ltd.; Pfizer, Inc.; Hospira, Inc.	Genentech, Inc.	Instituted	Final written decision	All inst. claims upheld
IPR2017-00807	Dymista®	8,168,620	2-Feb-17	APS GP LLC; Argentum Pharmaceuticals LLC; KVK-Tech, Inc.; et al.	Cipla Ltd.	Instituted	Settled post-institution	N/A
IPR2017-00822	Humira®	9,085,619	31-Jan-17	Coherus BioSciences, inc.	AbbVie Biotechnology Ltd.	Denied	N/A	N/A
IPR2017-00823	Humira®	9,085,619	31-Jan-17	Coherus BioSciences, inc.	AbbVie Biotechnology Ltd.	Denied	N/A	N/A
IPR2017-00826	Humira®	9,085,619	31-Jan-17	Coherus BioSciences, inc.	AbbVie Biotechnology Ltd.	N/A	Dismissed	N/A
IPR2017-00827	Humira®	9,085,619	31-Jan-17	Coherus BioSciences, inc.	AbbVie Biotechnology Ltd.	N/A	Dismissed	N/A

IPR2017-00853	Zytiga®	8,822,438	8-Feb-17	Amneal Holdings, LLC; Dr. Reddy's Laboratories, Inc.; Amneal Pharmaceutical Holdings Co., LLC; et al.	Janssen Oncology, Inc.	N/A	Claims disclaimed	N/A
IPR2017-00854	Gilenya™	9,187,405	3-Feb-17	Apotex Pharmaceuticals Holdings Inc.; Argentum Pharmaceuticals LLC; Sun Pharmaceutical Industries, Inc.; et al.	Novartis AG	Instituted	Final written decision	All inst. claims upheld
IPR2017-00900	Faslodex®	8,329,680	17-Feb-17	Pfizer Australia Pty Ltd.; Hospira, Inc.; InnoPharma Inc.; Pfizer, Inc.; et al.	Astrazeneca AB	Denied	N/A	N/A
IPR2017-00904	Faslodex®	6,774,122	17-Feb-17	Pfizer Australia Pty Ltd.; Hospira, Inc.; InnoPharma Inc.; Pfizer, Inc.; et al.	Astrazeneca AB	Denied	N/A	N/A
IPR2017-00905	Faslodex®	8,466,139	17-Feb-17	Pfizer Australia Pty Ltd.; Hospira, Inc.; InnoPharma Inc.; Pfizer, Inc.; et al.	Astrazeneca AB	Denied	N/A	N/A
IPR2017-00959	Herceptin®	8,591,897	21-Feb-17	Teva Pharmaceuticals International GmbH; Celltrion Healthcare Co., Ltd.; Celltrion, Inc.	Genentech, Inc.	N/A	Claims disclaimed	N/A
IPR2017-01008	Humira®	9,085,619	2-Mar-17	Coherus BioSciences, inc.	AbbVie Biotechnology Ltd.	Denied	N/A	N/A
IPR2017-01009	Humira®	9,085,619	2-Mar-17	Coherus BioSciences, inc.	AbbVie Biotechnology Ltd.	Denied	N/A	N/A
IPR2017-01034	Uceris®	8,784,888	9-Mar-17	Mylan N.V.; Mylan, Inc.; Mylan Pharmaceuticals, Inc.	Cosmo Technologies Ltd.	N/A	Settled pre-institution	N/A
IPR2017-01035	Uceris®	9,320,716	9-Mar-17	Mylan N.V.; Mylan, Inc.; Mylan Pharmaceuticals, Inc.	Cosmo Technologies Ltd.	Instituted	Settled post-institution	N/A
IPR2017-01053	Travatan Z®	8,268,299	10-Mar-17	APS GP LLC; Argentum Pharmaceuticals LLC; KVK-Tech, Inc.; et al.	Alcon Research Ltd.	Instituted	Final written decision	All inst. claims upheld
IPR2017-01054	Precedex™	8,242,158	8-Mar-17	Fresenius Kabi USA, LLC; Fresenius Kabi USA, Inc.; Fresenius SE & CO. KGaA; et al.	Hospira, Inc.	Denied	N/A	N/A
IPR2017-01055	Precedex™	8,338,470	8-Mar-17	Fresenius Kabi USA, LLC; Fresenius Kabi USA, Inc.; Fresenius SE & CO. KGaA; et al.	Hospira, Inc.	Denied	N/A	N/A
IPR2017-01056	Precedex™	8,455,527	8-Mar-17	Fresenius Kabi USA, LLC; Fresenius Kabi USA, Inc.; Fresenius SE & CO. KGaA; et al.	Hospira, Inc.	Denied	N/A	N/A

IPR2017-01063	Afinitor®	9,006,224	10-Mar-17	APS GP LLC; Argentum Pharmaceuticals LLC; KVK-Tech, Inc.; et al.	Novartis AG	Instituted	Final written decision	All inst. claims upheld
IPR2017-01078	Afinitor®	9,006,224	13-Mar-17	Roxane Laboratories, Inc.; West-Ward Pharmaceuticals Corp.; Hikma Pharmaceuticals PLC; et al.	Novartis AG	Instituted	Final written decision	All inst. claims upheld
IPR2017-01093	Rituxan™	9,329,172	15-Mar-17	Teva Pharmaceuticals International GmbH; Celltrio Healthcare Co., Ltd.; Celltrion, Inc.	Biogen, Inc.	Denied	N/A	N/A
IPR2017-01094	Rituxan™	8,557,244	15-Mar-17	Teva Pharmaceuticals International GmbH; Celltrio Healthcare Co., Ltd.; Celltrion, Inc.	Biogen, Inc.	Denied	N/A	N/A
IPR2017-01095	Rituxan™	9,296,821	15-Mar-17	Teva Pharmaceuticals International GmbH; Celltrio Healthcare Co., Ltd.; Celltrion, Inc.	Biogen, Inc.	Instituted	Final written decision	All inst. claims unpatentable
IPR2017-01100	Abraxane®	8,853,260	4-Apr-17	Ivax LLC; Actavis US Holding LLC; Teva Pharmaceuticals USA, Inc.; et al.	Abraxis Bioscience, LLC	Denied	N/A	N/A
IPR2017-01101	Abraxane®	7,820,788	4-Apr-17	Ivax LLC; Actavis US Holding LLC; Teva Pharmaceuticals USA, Inc.; et al.	Abraxis Bioscience, LLC	Instituted	Settled post-institution	N/A
IPR2017-01103	Abraxane®	7,923,536	4-Apr-17	Ivax LLC; Actavis US Holding LLC; Teva Pharmaceuticals USA, Inc.; et al.	Abraxis Bioscience, LLC	Instituted	Settled post-institution	N/A
IPR2017-01102		6,440,706	16-Mar-17	Myriad Genetics; Myriad Genetics Laboratories, Inc.; RainDance Technologies Inc.; Bio-Rad Laboratories Inc.	The John Hopkins University	N/A	Settled pre-institution	N/A
IPR2017-01104	Abraxane®	8,138,229	4-Apr-17	Ivax LLC; Actavis US Holding LLC; Teva Pharmaceuticals USA, Inc.; et al.	Abraxis Bioscience, LLC	Instituted	Settled post-institution	N/A
IPR2017-01105		8,859,206	16-Mar-17	Myriad Genetics; Myriad Genetics Laboratories, Inc.; RainDance Technologies Inc.; Bio-Rad Laboratories Inc.	The John Hopkins University	N/A	Settled pre-institution	N/A
IPR2017-01106		7,824,889	17-Mar-17	Myriad Genetics; Myriad Genetics Laboratories, Inc.; RainDance Technologies Inc.; Bio-Rad Laboratories Inc.	The John Hopkins University	N/A	Settled pre-institution	N/A

IPR2017-01107		7,915,015	17-Mar-17	Myriad Genetics; Myriad Genetics Laboratories, Inc.; RainDance Technologies Inc.; Bio-Rad Laboratories Inc.	The John Hopkins University	N/A	Settled pre-institution	N/A
IPR2017-01115	Rituxan™	7,820,161	24-Mar-17	Pfizer, Inc.	Biogen, Inc.	Instituted	Final written decision	All inst. claims patentable
IPR2017-01121	Herceptin®	7,846,441	21-Mar-17	Teva Pharmaceuticals International GmbH; Celltrion Healthcare Co., Ltd.; Celltrion, Inc.	Genentech, Inc.	Instituted	Final written decision	All inst. claims unpatentable
IPR2017-01122	Herceptin®	7,892,549	21-Mar-17	Teva Pharmaceuticals International GmbH; Celltrion Healthcare Co., Ltd.; Celltrion, Inc.	Genentech, Inc.	Instituted	Final written decision	All inst. claims unpatentable
IPR2017-01129		8,679,487	23-Mar-17	Regeneron Pharmaceuticals, Inc.; Genzyme Corp.; Sanofi-Aventis U.S. LLC	Immunex Corp.	Denied	N/A	N/A
IPR2017-01139	Herceptin®	6,627,196	24-Mar-17	Teva Pharmaceuticals International GmbH; Celltrion Healthcare Co., Ltd.; Celltrion, Inc.	Genentech, Inc.	Instituted	Final written decision	All inst. claims patentable
IPR2017-01140	Herceptin®	7,371,379	24-Mar-17	Teva Pharmaceuticals International GmbH; Celltrion Healthcare Co., Ltd.; Celltrion, Inc.	Genentech, Inc.	Instituted	Final written decision	All inst. claims patentable
IPR2017-01159	Ravicti®	9,254,278	27-Mar-17	Lupin Ltd.; Lupin Pharmaceuticals, Inc.	Horizon Therapeutics, LLC	Instituted	Settled post-institution	N/A
IPR2017-01160	Ravicti®	9,326,966	27-Mar-17	Lupin Ltd.; Lupin Pharmaceuticals, Inc.	Horizon Therapeutics, LLC	Instituted	Settled post-institution	N/A
IPR2017-01166	Rituxan™	8,329,172	21-Apr-17	Pfizer, Inc.	Biogen, Inc.	Denied	N/A	N/A
IPR2017-01167	Rituxan™	8,557,244	27-Apr-17	Pfizer, Inc.	Biogen, Inc.	Denied	N/A	N/A
IPR2017-01168	Rituxan™	8,821,873	28-Apr-17	Pfizer, Inc.	Biogen, Inc.	Instituted	Final written decision	All inst. claims unpatentable
IPR2017-01170		9,340,830	30-Mar-17	Guardant Health, Inc.	Foundation Medicine, Inc.	Instituted	Settled post-institution	N/A
IPR2017-01194		8,895,024	29-Mar-17	Merck Sharp & Dohme Corp.; Merck & Co Inc.	Wyeth LLC	Denied	N/A	N/A
IPR2017-01211		9,399,060	30-Mar-17	Merck Sharp & Dohme Corp.; Merck & Co Inc.	Wyeth LLC	Denied	N/A	N/A
IPR2017-01215		9,399,060	30-Mar-17	Merck Sharp & Dohme Corp.; Merck & Co Inc.	Wyeth LLC	Denied	N/A	N/A

IPR2017-01220		8,709,494	31-Mar-17	Vivex Biomedical International, Inc.; Advanced Numed Technologies Ltd.; UMTB Foundation; et al.	MiMedx Group, Inc.	N/A	Settled pre-institution	N/A
IPR2017-01223		9,399,060	31-Mar-17	Merck Sharp & Dohme Corp.; Merck & Co Inc.	Wyeth LLC	Denied	N/A	N/A
IPR2017-01227	Rituxan™	7,682,612	31-Mar-17	Teva Pharmaceuticals International GmbH; Celltrion Healthcare Co., Ltd.; Celltrion, Inc.	Biogen, Inc.; Genentech, Inc.	Denied	N/A	N/A
IPR2017-01229	Rituxan™	8,206,711	31-Mar-17	Teva Pharmaceuticals International GmbH; Celltrion Healthcare Co., Ltd.; Celltrion, Inc.	Biogen, Inc.; Genentech, Inc.	Denied	N/A	N/A
IPR2017-01230	Rituxan™	7,682,612	31-Mar-17	Teva Pharmaceuticals International GmbH; Celltrion Healthcare Co., Ltd.; Celltrion, Inc.	Biogen, Inc.; Genentech, Inc.	Denied	N/A	N/A
IPR2017-01252		6,946,292	6-Apr-17	Transposagen Biopharmaceuticals, Inc.; Aragen Bioscience, Inc.; GVK Biosciences, Private Ltd.; et al.	Kyowa Hakko Kirin Co., Ltd.	Denied	N/A	N/A
IPR2017-01254		8,067,232	6-Apr-17	Transposagen Biopharmaceuticals, Inc.; Aragen Bioscience, Inc.; GVK Biosciences, Private Ltd.; et al.	Kyowa Hakko Kirin Co., Ltd.	Denied	N/A	N/A
IPR2017-01256		9,249,149	7-Apr-17	Incyte Corporation	Concert Pharmaceuticals, Inc.	Denied	N/A	N/A
IPR2017-01262		7,425,446	11-Apr-17	Transposagen Biopharmaceuticals, Inc.; Aragen Bioscience, Inc.; GVK Biosciences, Private Ltd.; et al.	Kyowa Hakko Kirin Co., Ltd.	Denied	N/A	N/A
IPR2017-01292	Latuda®	9,555,027	18-Apr-17	Endo Luxembourge Holding Co. S.a.r.l.; Paladin Labs Inc.; et al.	Sumitomo Dainippon Pharma Co., Ltd.	N/A	Settled pre-institution	N/A
IPR2017-01332		8,404,618	28-Apr-17	Bayer Cropscience LP; Bayer Corp.; Bayer AG; et al.	Syngenta Crop Protection, LLC; Syngenta Ltd.	Denied	N/A	N/A
IPR2017-01357		7,332,289	19-May-17	Pfizer, Inc.	Chugai Pharmaceutical Co., Ltd.	Instituted	Final written decision	All inst. claims patentable

IPR2017-01358		7,927,815	19-May-17	Pfizer, Inc.	Chugai Pharmaceutical Co., Ltd.	Instituted	Final written decision	All inst. claims patentable
IPR2017-01373	Herceptin®	6,407,213	8-May-17	Teva Pharmaceuticals International GmbH; Celltrion Healthcare Co., Ltd.; Celltrion, Inc.	Genentech, Inc.	Instituted	Final written decision	Some claims upheld
IPR2017-01374	Herceptin®	6,407,213	8-May-17	Teva Pharmaceuticals International GmbH; Celltrion Healthcare Co., Ltd.; Celltrion, Inc.	Genentech, Inc.	Instituted	Final written decision	Some claims upheld
IPR2017-01429	Jublia®	7,214,506	12-May-17	APS GP LLC; Argentum Pharmaceuticals LLC; Intelligent Pharma Research LLC; et al.	Kaken Pharmaceutical Co., Ltd; Valeant Pharmaceuticals Int'l	Instituted	Final written decision	All inst. claims unpatentable
IPR2017-01434	Zioptan®	5,886,035	12-May-17	Micro Labs Ltd.; Micro Labs USA Inc.	Santen Pharmaceutical Co., Ltd.; Asahi Glass Co. Ltd.	Instituted	Final written decision	All inst. claims patentable
IPR2017-01446	Ferriprox®	7,049,328	16-May-17	Taro Pharmaceutical Industries, Ltd.; Sun Pharmaceuticals, Inc.; et al.	Apotex Technologies, Inc.	Instituted	Settled post-institution	N/A
IPR2017-01447		9,340,830	17-May-17	Guardant Health, Inc.	Foundation Medicine, Inc.	Instituted	Settled post-institution	N/A
IPR2017-01448		9,340,830	17-May-17	Guardant Health, Inc.	Foundation Medicine, Inc.	Instituted	Settled post-institution	N/A
IPR2017-01488	Herceptin®	6,407,213	25-May-17	Pfizer, Inc.	Genentech, Inc.	Instituted	Final written decision	Some claims upheld
IPR2017-01489	Herceptin®	9,407,213	25-May-17	Pfizer, Inc.	Genentech, Inc.	Instituted	Final written decision	Some claims upheld
IPR2017-01506		7,608,436	30-May-17	Roquette Frères, S.A.	Tate & Lyle Ingredients Americas LLC	Instituted	Procedurally dismissed	N/A
IPR2017-01512		9,616,111	31-May-17	CSL Behring GmbH; CSL Behring LLC	Shire ViroPharma Inc.	Denied	N/A	N/A
IPR2017-01526	Lantus®	7,476,652	5-Jun-17	Biocon Research Ltd.; Biocon Ltd.; Mylan Pharmaceuticals, Inc.; Mylan N.V.; et al.	Sanofi-Aventis Deutschland GmbH	Instituted	Final written decision	All inst. claims unpatentable
IPR2017-01528	Lantus®	7,713,930	5-Jun-17	Biocon Research Ltd.; Biocon Ltd.; Mylan Pharmaceuticals, Inc.; Mylan N.V.; et al.	Sanofi-Aventis Deutschland GmbH	Instituted	Final written decision	All inst. claims unpatentable
IPR2017-01550	Gilenya™	9,187,405	9-Jun-17	APS GP LLC; Argentum Pharmaceuticals LLC; KVK-Tech, Inc.; et al.	Novartis AG	Instituted	Final written decision	All inst. claims patentable
IPR2017-01551		6,180,373	30-Jun-17	CJ CheilJedang Corp.; PT CheilJedang Indonesia; CJ America, Inc.	Ajinomoto USA, Inc.	Denied	N/A	N/A
IPR2017-01557	Suboxone®	8,603,514	9-Jun-17	Endo Luxembourg Holding Co. S.a.r.l.; Paladin Labs Inc.; et al.	MonoSol Rx LLC	Denied	N/A	N/A

IPR2017-01582	Suboxone®	8,603,514	12-Jun-17	Dr. Reddy's Laboratories, Inc.; Dr. Reddy's Laboratories, Ltd.	MonoSol Rx LLC	Denied	N/A	N/A
IPR2017-01592	Afinitor®	8,410,131	12-Jun-17	Breckenridge Pharmaceutical, Inc.; Natco Pharma Ltd.; et al.	Novartis Pharmaceuticals Corporation	Instituted	Settled post-institution	N/A
IPR2017-01598		8,168,381	13-Jun-17	Nuevolution A/S	Chemgene Holding APS	Instituted	Final written decision	Some claims upheld
IPR2017-01599		8,168,381	13-Jun-17	Nuevolution A/S	Chemgene Holding APS	Instituted	Final written decision	All inst. claims unpatentable
IPR2017-01603		8,951,728	14-Jun-17	Nuevolution A/S	Chemgene Holding APS	Instituted	Final written decision	All inst. claims unpatentable
IPR2017-01621	Tyvaso®	9,358,240	21-Jun-17	Barr Laboratories, Inc.; Teva Pharmaceuticals USA, Inc.; PLIVA-HRVATSKA d.o.o.; et al.	United Therapeutics Corporation	Instituted	Settled post-institution	N/A
IPR2017-01622	Tyvaso®	9,339,507	21-Jun-17	Barr Laboratories, Inc.; Teva Pharmaceuticals USA, Inc.; PLIVA-HRVATSKA d.o.o.; et al.	United Therapeutics Corporation	Instituted	Settled post-institution	N/A
IPR2017-01648	Fortamet®; Actoplus Met® XR	6,866,866	22-Jun-17	Aurobindo Pharma Ltd.; Aurobindo Pharma USA Inc.	Andrx Labs, LLC	Instituted	Final written decision	All inst. claims patentable
IPR2017-01673	Fortamet®; Actoplus Met® XR	6,790,459	23-Jun-17	Aurobindo Pharma Ltd.; Aurobindo Pharma USA Inc.	Andrx Labs, LLC	Denied	N/A	N/A
IPR2017-01698		7,666,655	30-Jun-17	CJ CheilJedang Corp.; PT CheilJedang Indonesia; CJ America, Inc.	Ajinomoto USA, Inc.	Denied	N/A	N/A
IPR2017-01712		8,815,830	30-Jun-17	Gilead Sciences, Inc.	Regents of the University of Minnesota	Instituted	Pending	N/A
IPR2017-01726	Herceptin®	8,591,897	30-Jun-17	Pfizer, Inc.	Genentech, Inc.	Denied	N/A	N/A
IPR2017-01727	Herceptin®	8,591,897	30-Jun-17	Pfizer, Inc.	Genentech, Inc.	Denied	N/A	N/A
IPR2017-01746		6,017,221	10-Jul-17	Samsung Electronics America, Inc.; Samsuch Electronics Co., Ltd.; Samsung Semiconductor, Inc.; et al.	Daniel L. Flamm	Instituted	Final written decision	All claims unpatentable
IPR2017-01753		8,815,830	7-Jul-17	Gilead Sciences, Inc.	Regents of the University of Minnesota	Denied	N/A	N/A
IPR2017-01757	Cialis®	6,943,166	10-Jul-17	Dr. Reddy's Laboratories, Inc.; Dr. Reddy's Laboratories, Ltd. (India); et al.	ICOS Corporation	N/A	Settled pre-institution	N/A
IPR2017-01762	Cialis®	6,943,166	12-Jul-17	APS GP LLC; Argentum Pharmaceuticals LLC; et al.	ICOS Corporation	N/A	Settled pre-institution	N/A
IPR2017-01767	Ravicti®	9,254,278	13-Jul-17	Endo Luxembourg Holding Co. S.a.r.l.; Paladin Labs Inc.; et al.	Horizon Therapeutics, LLC	Instituted	Settled post-institution	N/A

IPR2017-01768	Ravicti®	9,095,559	13-Jul-17	Endo Luxembourg Holding Co. S.a.r.l.; Paladin Labs Inc.; et al.	Horizon Therapeutics, LLC	Instituted	Settled post-institution	N/A
IPR2017-01769	Ravicti®	9,326,966	13-Jul-17	Endo Luxembourg Holding Co. S.a.r.l.; Paladin Labs Inc.; et al.	Horizon Therapeutics, LLC	Instituted	Settled post-institution	N/A
IPR2017-01795		8,383,086	17-Jul-17	Elysium Health, Inc.	Trustees of Dartmouth College	Instituted	Final written decision	Some claims upheld
IPR2017-01796		8,197,807	17-Jul-17	Elysium Health, Inc.	Trustees of Dartmouth College	Denied	N/A	N/A
IPR2017-01823	Humira®	8,802,100	20-Jul-17	Sandoz, Inc.	AbbVie Biotechnology Ltd.	Denied	N/A	N/A
IPR2017-01824	Humira®	9,512,216	20-Jul-17	Sandoz, Inc.	AbbVie Biotechnology Ltd.	Denied	N/A	N/A
IPR2017-01878		5,894,017	27-Jul-17	Ranir, LLC	The Procter & Gamble Co.	Instituted	Settled post-institution	N/A
IPR2017-01879	Dupixent®	8,679,487	28-Jul-17	Regeneron Pharmaceuticals, Inc.; Genzyme Corp.; Sanofi-Aventis U.S. LLC	Immunex Corp.	Instituted	Final written decision	All inst. claims upheld
IPR2017-01884	Dupixent®	8,679,487	31-Jul-17	Regeneron Pharmaceuticals, Inc.; Genzyme Corp.; Sanofi-Aventis U.S. LLC	Immunex Corp.	Instituted	Final written decision	All claims unpatentable
IPR2017-01906		8,357,795	2-Aug-17	Teoxane S.A.	Allergan Industrie SAS	Denied	N/A	N/A
IPR2017-01910	Faslodex®	6,774,122	4-Aug-17	Fresenius Kabi USA, LLC	Astrazeneca AB	Denied	N/A	N/A
IPR2017-01912	Faslodex®	8,466,139	4-Aug-17	Fresenius Kabi USA, LLC	Astrazeneca AB	Denied	N/A	N/A
IPR2017-01913	Faslodex®	8,329,680	4-Aug-17	Fresenius Kabi USA, LLC	Astrazeneca AB	Denied	N/A	N/A
IPR2017-01916	Enbrel®	8,163,522	4-Aug-17	Coherus BioSciences, inc.	Hoffman-La Roche Inc.	Denied	N/A	N/A
IPR2017-01919		9,394,216	8-Aug-17	Decco U.S. Post-Harvest, Inc.; Cerexagri, Inc.; UPL Ltd.	Mirtech, Inc.	Instituted	Final written decision	All claims unpatentable
IPR2017-01923	Rituxan™	7,976,838	29-Aug-17	Pfizer, Inc.	Genentech, Inc.	Instituted	Final written decision	All inst. claims upheld
IPR2017-01929	Gilenya™	9,187,405	16-Aug-17	Sun Pharmaceutical Industries Ltd.; Sun Pharma Global FZE; Sun Pharmaceutical Industries, Inc.	Novartis Pharmaceuticals Corporation	Instituted	Final written decision	All inst. claims upheld
IPR2017-01946	Gilenya™	9,187,405	15-Aug-17	Ivax LLC; Actavis US Holding LLC; Teva Pharmaceuticals USA, Inc.; et al.	Novartis Pharmaceuticals Corporation	Instituted	Final written decision	All inst. claims upheld
IPR2017-01958	Herceptin®	6,627,196	25-Aug-17	Samsung Bioepis Co., Ltd.	Genentech, Inc.	Instituted	Final written decision	All inst. claims upheld
IPR2017-01959	Herceptin®	7,371,379	25-Aug-17	Samsung Bioepis Co., Ltd.	Genentech, Inc.	Instituted	Final written decision	All inst. claims upheld
IPR2017-01960	Herceptin®	7,892,549	25-Aug-17	Samsung Bioepis Co., Ltd.	Genentech, Inc.	Instituted	Final written decision	All claims unpatentable
IPR2017-01987	Humira®	8,911,737	21-Aug-17	Sandoz, Inc.	AbbVie Biotechnology Ltd.	Denied	N/A	N/A
IPR2017-01988	Humira®	8,974,790	21-Aug-17	Sandoz, Inc.	AbbVie Biotechnology Ltd.	Denied	N/A	N/A

IPR2017-01995	Vimovo®	9,220,698	24-Aug-17	Mylan Pharmaceuticals, Inc.; Mylan Laboratories Ltd.; Mylan Inc.; Mylan N.V.	Horizon Pharma, Inc.; Pozen Inc.	Instituted	Settled post-institution	N/A
IPR2017-02002		8,450,475	24-Aug-17	Teoxane S.A.	Allergan PLC	Denied	N/A	N/A
IPR2017-02004		8,815,830	28-Aug-17	Gilead Sciences, Inc.	Regents of the University of Minnesota	Denied	N/A	N/A
IPR2017-02005		8,815,830	29-Aug-17	Gilead Sciences, Inc.	Regents of the University of Minnesota	Denied	N/A	N/A
IPR2017-02019	Herceptin®	6,339,142	29-Aug-17	Pfizer, Inc.	Genentech, Inc.	Instituted	Settled post-institution	N/A
IPR2017-02020	Herceptin®	9,249,218	29-Aug-17	Pfizer, Inc.	Genentech, Inc.	Instituted	Settled post-institution	N/A
IPR2017-02029		6,870,034	31-Aug-17	Boehringer Ingelheim Pharma GmbH & Co. KG; Boehringer Ingelheim Corp.; et al.	Genentech, Inc.	Instituted	Settled post-institution	N/A
IPR2017-02031		6,407,213	31-Aug-17	Boehringer Ingelheim Pharma GmbH & Co. KG; Boehringer Ingelheim Corp.; et al.	Genentech, Inc.	Instituted	Procedurally dismissed	All inst. claims patentable
IPR2017-02032		6,407,213	31-Aug-17	Boehringer Ingelheim Pharma GmbH & Co. KG; Boehringer Ingelheim Corp.; et al.	Genentech, Inc.	Instituted	Procedurally dismissed	All inst. claims patentable
IPR2017-02036	Rituxan™	7,976,838	31-Aug-17	Sandoz, Inc.	Genentech, Inc.	Denied	N/A	N/A
IPR2017-02042	Rituxan™	7,976,838	31-Aug-17	Sandoz, Inc.	Genentech, Inc.	Denied	N/A	N/A
IPR2017-02063	Herceptin®	7,846,441	6-Sep-17	Pfizer, Inc.	Genentech, Inc.	Instituted	Final written decision	All claims unpatentable
IPR2017-02066	Enbrel®	8,063,182	7-Sep-17	Coherus BioSciences, inc.	Hoffman-La Roche Inc.	Denied	N/A	N/A
IPR2017-02086		6,440,706	11-Sep-17	Ambry Genetics Corp.	The John Hopkins University	Instituted	Settled post-institution	N/A
IPR2017-02093		7,824,889	11-Sep-17	Ambry Genetics Corp.	The John Hopkins University	Instituted	Settled post-institution	N/A
IPR2017-02095		7,915,015	11-Sep-17	Ambry Genetics Corp.	The John Hopkins University	Denied	N/A	N/A
IPR2017-02096		8,859,206	11-Sep-17	Ambry Genetics Corp.	The John Hopkins University	Denied	N/A	N/A
IPR2017-02105	Humira®	9,090,689	14-Sep-17	Sandoz, Inc.	AbbVie Biotechnology Ltd.	Instituted	Settled post-institution	N/A
IPR2017-02106	Humira®	9,067,992	14-Sep-17	Sandoz, Inc.	AbbVie Biotechnology Ltd.	Instituted	Settled post-institution	N/A
IPR2017-02126	Rituxan™	7,682,612	6-Oct-17	Pfizer, Inc.	BioGenex, Inc.; Genentech, Inc.	Denied	N/A	N/A
IPR2017-02127	Rituxan™	8,206,711	6-Oct-17	Pfizer, Inc.	BioGenex, Inc.; Genentech, Inc.	Denied	N/A	N/A
IPR2017-02131		9,492,559	19-Sep-17	Merck Sharp & Dohme Corp.; Merck & Co Inc.	Pfizer, Inc.	Instituted	Final written decision	All claims unpatentable
IPR2017-02132		9,492,559	19-Sep-17	Merck Sharp & Dohme Corp.; Merck & Co Inc.	Pfizer, Inc.	Instituted	Final written decision	All claims unpatentable
IPR2017-02136		9,492,559	20-Sep-17	Merck Sharp & Dohme Corp.; Merck & Co Inc.	Pfizer, Inc.	Instituted	Final written decision	All claims unpatentable
IPR2017-02138		9,492,559	20-Sep-17	Merck Sharp & Dohme Corp.; Merck & Co Inc.	Pfizer, Inc.	Instituted	Final written decision	All claims unpatentable
IPR2017-02139	Herceptin®	6,407,213	29-Sep-17	Samsung Bioepis Co., Ltd.	Genentech, Inc.	Instituted	Final written decision	Some claims upheld

IPR2017-02140	Herceptin®	6,407,213	29-Sep-17	Samsung Bioepis Co., Ltd.	Genentech, Inc.	Instituted	Final written decision	Some claims upheld
IPR2017-02172		7,566,537	5-Oct-17	BGI Americas Corp; BGI Genomics Co., Ltd.; et al.	Illumina Cambridge Ltd.	Denied	N/A	N/A
IPR2017-02174		7,566,537	5-Oct-17	BGI Americas Corp; BGI Genomics Co., Ltd.; et al.	Illumina Cambridge Ltd.	Denied	N/A	N/A
IPR2017-02176		7,777,098	25-Sep-17	Nufarm Ltd; Nuseed Americas Inc.	BASF Plant Science GmbH	Instituted	Final written decision	All claims unpatentable
IPR2017-02184		7,208,265	10-Oct-17	ABS Global, Inc.; Genus plc	XY, LLC	Instituted	Claims disclaimed	N/A
IPR2017-02194		8,383,340	29-Sep-17	ModernaTX, Inc.	CureVac AG	Instituted	Final written decision	All claims unpatentable